Report cover image

Nontuberculous Mycobacterial Infections - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18679870

Description

Nontuberculous Mycobacterial Infections - Pipeline Insight, 2024



DelveInsight’s, “Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Nontuberculous Mycobacteria (NTM) Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Nontuberculous Mycobacteria (NTM) Infections Understanding

Nontuberculous Mycobacteria (NTM) Infections: Overview

Non-tuberculous mycobacteria (NTM) are ubiquitous, free living, environmental saprophytic organisms known to occupy water systems, soil, and vegetation. Infections caused by NTM is known as Nontuberculous Mycobacteria (NTM) Infections. NTM disease presents a wide variety of clinical syndromes, from lymphadenopathy (commonly cervical lymph nodes) to aseptic meningitis. Diagnosis of nontuberculous mycobacterial (NTM) lung disease include chest radiograph, three or more sputum specimens for acid-fast bacilli (AFB) analysis and exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. Treatment for NTM infections generally prolonged (12–18 months) multi-drug therapy. Disease remission rates vary depending on infecting species, patient age and comorbidities.

""Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria (NTM) Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria (NTM) Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria (NTM) Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacteria (NTM) Infections R&D. The therapies under development are focused on novel approaches to treat/improve Nontuberculous Mycobacteria (NTM) Infections.
Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs Chapters

This segment of the Nontuberculous Mycobacteria (NTM) Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs
  • RHB 204: RedHill Biopharma
RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine. The drug is in Phase III development for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections caused by Mycobacterium avium Complex (MAC). RHB-204 was granted both FDA Orphan Drug Designation for the treatment of NTM disease and QIDP Designation under the Generating Antibiotic Incentives Now Act (GAIN Act).
  • MAT2501: Matinas BioPharma
MAT2501 is an orally-administered Lipid Nano-Crystal formulation of the gram-negative antibiotic agent, amikacin. The drug is in Phase I clinical development for the treatment of Nontuberculous Mycobacteria (NTM) Infections. As a broad-spectrum aminoglycoside, amikacin is highly effective in treating a range of chronic and acute bacterial infections, including Non-Tuberculous Mycobacterium (NTM) infections. FDA designated MAT2501 as a QIDP and Orphan Drug for the treatment of NTM infections.

Further product details are provided in the report……..

Nontuberculous Mycobacteria (NTM) Infections: Therapeutic Assessment

This segment of the report provides insights about the different Nontuberculous Mycobacteria (NTM) Infections drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Nontuberculous Mycobacteria (NTM) Infections
There are approx. 14+ key companies which are developing the therapies for Nontuberculous Mycobacteria (NTM) Infections. The companies which have their Nontuberculous Mycobacteria (NTM) Infections drug candidates in the most advanced stage, i.e. Phase III include, RedHill Biopharma.
  • Phases
DelveInsight’s report covers around 14+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Nontuberculous Mycobacteria (NTM) Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nontuberculous Mycobacteria (NTM) Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.

Nontuberculous Mycobacteria (NTM) Infections Report Insights
  • Nontuberculous Mycobacteria (NTM) Infections Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Nontuberculous Mycobacteria (NTM) Infections Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Nontuberculous Mycobacteria (NTM) Infections drugs?
  • How many Nontuberculous Mycobacteria (NTM) Infections drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nontuberculous Mycobacteria (NTM) Infections?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nontuberculous Mycobacteria (NTM) Infections therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nontuberculous Mycobacteria (NTM) Infections and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • RedHill Biopharma
  • Janssen Pharmaceutical
  • Spero Therapeutics
  • Revimmune
  • Matinas BioPharma
  • MannKind Corporation
  • Spero Therapeutics
  • Shionogi
  • Crestone
Key Products
  • RHB 204
  • Bedaquiline
  • SPR 720
  • CYT107
  • MAT2501
  • MNKD-10
  • SPR-719
  • Research programme: mycobacterial disease therapeutics
  • MmpL3 inhibitor

Table of Contents

50 Pages
Introduction
Executive Summary
Nontuberculous Mycobacteria (NTM) Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nontuberculous Mycobacteria (NTM) Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nontuberculous Mycobacteria (NTM) Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nontuberculous Mycobacteria (NTM) Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
RHB 204: RedHill Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CYT107: Revimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
MAT2501: Matinas BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
MNKD-10: MannKind Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Nontuberculous Mycobacteria (NTM) Infections Key Products
Nontuberculous Mycobacteria (NTM) Infections- Unmet Needs
Nontuberculous Mycobacteria (NTM) Infections- Market Drivers and Barriers
Nontuberculous Mycobacteria (NTM) Infections- Future Perspectives and Conclusion
Nontuberculous Mycobacteria (NTM) Infections Analyst Views
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us